Publication date: 24 September, 2026
Autoimmune & inflammatory diseases
The next wave of immune-mediated therapies
Autoimmune and inflammatory diseases remain one of Europe’s most active areas of biotech innovation. From inflammatory bowel disease, psoriasis and atopic dermatitis to lupus, vasculitis, multiple sclerosis and rare immune-mediated disorders, European companies are helping reshape how chronic inflammation is understood and treated. The field is moving beyond broad immunosuppression towards more precise approaches: targeted antibodies, cytokine modulators, complement inhibitors, RNA medicines, microbiome-linked therapies, new biomarkers and AI-supported innovation. In its Autumn 2026 issue, European Biotechnology Magazine will spotlight the companies, technologies and clinical programmes driving this shift across Europe.
Present your expertise
Drug developers, diagnostics specialists, investors, technology providers and service partners active in autoimmune and inflammatory diseases will have the opportunity to present their latest products, processes, and innovations in this special feature, which will find extra circulation at BIO-Europe 2026. European Biotechnology Magazine goes out to decision makers throughout the European life sciences sector and through our official partner, SLAS, in the USA. Take advantage of the journal’s highly relevant readership and grab this opportunity to target your audience!
Examples of topics
Targeted immunology, cytokine biology, T-cell modulation, B-cell therapies, complement biology, inflammasome inhibition, inflammatory bowel disease, dermatology, rheumatology, neuroinflammation, rare autoimmune disorders, biomarkers, companion diagnostics, microbiome approaches, bispecific antibodies, AI-supported drug discovery, clinical trial design, regulatory strategy, etc.
Editorial Deadline 10-09-2026
Editorial contact::
Booking Deadline 10-09-2026
Marketing contact:
Publication Date 24-09-2026
Marketing contact: Joachim Eeckhout Oliver Schnell Andreas Macht
Tel.: +49-30-264921-29 Tel.: +49-30-264921-45
Tel.: +49-30-264921-54
joachim.eeckhout@knowb.io oliver.schnell@knowb.io andreas.macht@knowb.io
